2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
7
Esophageal Neoplasms
4
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Adenocarcinoma
2
Solid Tumor
1
Rectal Neoplasms
1
Patients With Advanced or Metastatic Solid Tumors
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Carcinoma
1
Locally Advanced Gastric Adenocarcinoma
1
Hand-Foot Syndrome
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
30
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Radiotherapy
16
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Nivolumab
13
Ramucirumab
11
Cyclophosphamide
11
Drug Therapy
9
Trastuzumab
8
Erlotinib Hydrochloride
8
zolbetuximab
7
Taxes
7
Radiosurgery
7
trastuzumab deruxtecan
6
cemiplimab
6
Blood Specimen Collection
6
regorafenib
5
durvalumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
tegafur-gimeracil-oteracil
×
Clear all
NCT05161572
2025-06-18
NeoRacing
Fudan University
Phase 2
Terminated
6 enrolled
NCT02564367
2021-04-29
S-1 adjuvant
AIO-Studien-gGmbH
Phase 1/2
Completed
30 enrolled